Next Article in Journal
Boron Neutron Capture Therapy: Clinical Application and Research Progress
Next Article in Special Issue
Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?
Previous Article in Journal
Complications and Risk Factors in En Bloc Resection of Spinal Tumors: A Retrospective Analysis on 298 Patients Treated in a Single Institution
Previous Article in Special Issue
Efficacy and Safety of the Addition of Internal Mammary Irradiation to Standard Adjuvant Radiation in Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 29
Issue 10
10.3390/curroncol29100621
Review Report
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial

Curr. Oncol. 2022, 29(10), 7858-7867; https://doi.org/10.3390/curroncol29100621
by Davide Franceschini 1,*, Tiziana Comito 1, Anna Di Gallo 1,2, Veronica Vernier 1,2, Marco A. Marzo 1,2, Luciana Di Cristina 1,2, Beatrice Marini 1,2, Lorenzo Lo Faro 1,2, Sara Stefanini 1,2, Ruggero Spoto 1, Luca Dominici 1, Ciro Franzese 1,2 and Marta Scorsetti 1,2
Reviewer 1:
Daniele Scartoni
Reviewer 2: Anonymous
Curr. Oncol. 2022, 29(10), 7858-7867; https://doi.org/10.3390/curroncol29100621
Submission received: 6 September 2022 / Revised: 10 October 2022 / Accepted: 14 October 2022 / Published: 17 October 2022
(This article belongs to the Special Issue Radiation Therapy for Breast Cancer: Current Status and Future Perspectives)

Round 1

Reviewer 1 Report

Did you use MRI for simulation of liver lesions?

How did you categorized metastatic disease? Could you clarify?

How did you differentiate synchronous and metachronous disease?
Can you add a table with dose and fractionation utilized and relative percentages of patients?

Author Response

Thanks for your precious comments.

We did our best to follow your recommendations, as follows.

Did you use MRI for simulation of liver lesions?

Yes, when deemed helpful for simulation purposes and in absence of contraindications. Now clarified in the matherial and methods

How did you categorized metastatic disease? Could you clarify?

We followed the ESTRO-EORTC classification. Now clarified in the manuscript and added in the references

How did you differentiate synchronous and metachronous disease?

Disease was considered synchronous if metastases were diagnosed within 6 months from primary cancer occurrence. Added in the matherial and methods section

Can you add a table with dose and fractionation utilized and relative percentages of patients?

Required informations have been added in table 4.

Reviewer 2 Report

This manuscript is about Phase II non randomized trial of the treatment of liver and lung metastases from breast cancer with stereotactic body radiotherapy. The Authors did a great job with illustrating and explaining in their manuscript about the methods, side effects and the constraints of the radiotherapy. Since the development in the technic in the field of radiotherapy and the safety of the procedures due to the development in the software and hardware of the radiotherapy. This lead to deliver a high precision therapy for secondary tumors whether in the liver or lung without causing a high grade side effects. There was no grade III side effects. I recommended this manuscript to be publish.

Author Response

Thank you very much for your observations

Back to TopTop